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Summary Epstein-Barr (EB) virus was discovered in 1964 (Epstein et al., 1964). In the decades since then an
immense body of information has been accumulated on the virus and a great deal is now known about its
general biological behaviour, its epidemiology, its molecular biology, the humoral and cellular immunological
responses which it evokes, and about its relationship to human cancers. The fact that EB virus was thought
from the outset to be a human tumour virus was no doubt responsible for the large number of laboratories in
which it has been studied. Viruses causing tumours in animals have been known since early in the present
century and affect frogs, fowl, rodents, rabbits, cats, cattle, monkeys and even fish (Klein, 1980). It was
obvious that man could not be different in this respect and the finding of EB virus therefore promised to
bring human tumours into line with those of other species.
Epstein-Barr virus and cancer in man
As is well known, EB virus was first found in cells
from endemic Burkitt's lymphoma (BL) (Epstein et
al., 1964) during a search for a possible causative
viral agent undertaken because the peculiar epi-
demiology of the tumour suggested it might be
associated with an infection (Burkitt, 1962 a,b).
Shortly after this the investigation of antibodies in
various patients implicated EB virus as a possible
factor in the induction of another human tumour,
undifferentiated nasopharyngeal carcinoma (NPC)
(Old et al., 1966). Since the early days when EB
virus was merely a suspect, the evidence indicating
that it plays an oncogenic role in man has strength-
ened year by year. Major milestones were the
finding of the viral DNA in the tumour cells of BL
(zur Hausen et al., 1970), the massive seven-year
WHO prospective study of 42,000 children in the
West Nile district of Uganda which established that
certain reaction patterns to EB virus infection con-
stituted a large risk factor for developing BL (de-
The et al., 1978), the identification of hyperendemic
malaria as the cofactor responsible for determining
the geographical distribution of the tumour
(Burkitt, 1969), and the more recent elucidation -
discussed below - of how malaria might act in this
respect.
Enough has been learned about EB virus in
relation to endemic BL for a persuasive aetiological
theory to have emerged. Thus, it has been
suggested (Klein, 1983) that latently infected B cells
are driven by the virus to undergo unusually
abundant replication such that one or other of
three specific chromosomal translocations comes
about, each being a cause of c-myc oncogene
activation. According to this view, the activated
c-myc, perhaps cooperating with some other
oncogene, brings about the final step to malig-
nancy. But it should be remembered that serious
doubts have been raised as to whether cellular
oncogenes are relevant at all to the induction of
cancer (Duesberg, 1985) and certainly c-myc alone
cannot render cells cancerous (Adams et al., 1985).
But whatever the pathway, it is clear that EB virus
is an indispensable link in the chain of events
leading to tumour induction.
As far as NPC is concerned, rather little has
hitherto been known. The viral DNA is of course
present in all the malignant epithelial cells of this
tumour (Wolf et al., 1973), and the pattern of
antibody responses to the virus displayed by
patients is unique and special; indeed, this antibody
pattern is already being used for mass population
screening to detect those with an increased risk of
developing the tumour or those in the early stages
of undiagnosed NPC (Zeng et al., 1982). Following
antibody patterns is also important for the clinical
assessment of NPC patients after treatment.
Quite recent findings on EB virus and human
tumours have clarified many hitherto puzzling
problems. It has long been thought that virus
receptors were only present on the surface of B
lymphocytes and the way in which the epithelial
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cells of NPC acquired the EB virus genome was a
total enigma. The B cell virus receptor has recently
been shown to be the complement C3d receptor
molecule CR2 (Fingeroth et al., 1984), and using
two monoclonal antibodies against different
epitopes of this receptor it has now been demon-
strated that such receptors are also present on the
cells of oral and naspharyngeal squamous epithelia
(Young et al., 1986). New information (Wang et al.,
1985) on a key EB virus gene is perhaps even more
important; this gene codes for the virus-determined
membrane protein of latently infected cells and has
now been identified and cloned, and after trans-
fection into quite alien cells expression of the
product has been shown to confer tumourigenicity
(Wang et al., 1985). This transforming gene would
seem to explain the ability of EB virus to cause
malignant tumours rapidly and directly in sus-
ceptible animals (Cleary et al., 1985) and clearly
plays a major role in the chain of events leading to
the development of endemic Burkitt's lymphoma,
whether with or without interaction with an acti-
vated c-myc oncogene. Discovery of this gene also
provides a first and important indication as to how
EB virus might be involved in causing NPC, al-
though here, too, it is clear on epidemiological
grounds that an environmental co-factor also
operates (Henderson, 1984).
In the past few years it has come to be recog-
nized that specific cytotoxic T cells are of crucial
importance in maintaining the virus-host balance
which permits the infected individual to live with
the life-long infection which EB virus always estab-
lishes. This balance is delicate and impairment of T
cell surveillance predisposes to virus-induced
pathology. For example, it has been amply demon-
strated that transplant recipients on immuno-
suppressive therapy to prevent graft rejection have
depressed numbers of EB virus-specific cytotoxic T
cells (Crawford et al., 1981; Gaston et al., 1982),
and that they also show a heightened incidence of
EB virus-associated lymphomas (Klein & Purtilo,
1981). Similarly in AIDS, cytotoxic lymphocytes are
depleted, and here too lymphomas carrying EB
virus are unusually common (Ziegler et al., 1984).
In this connection it is of great interest that attacks
of falciparum malaria are now known likewise to
be accompanied by a fall in T cell numbers and
inversion of the T4/T8 ratio (Whittle et al., 1984),
and it would seem that in hyperendemic malaria,
the repeated attacks throughout the year, and year
after year, profoundly affect the normal EB virus
cellular surveillance mechanisms. In combination
with the newly described EB virus transforming
gene (Wang et al., 1985), it is not difficult to see
how these events could lead to the emergence of the
malignant cells of BL.
A vaccine against EB virus
Already by 1976 the links between the virus and
both BL and NPC were so strong that it seemed
essential to consider the development of an anti-
viral vaccine designed to prevent infection and
hopefully thereby reduce the incidence of the
tumours. Proposals were made at that time
(Epstein, 1976) drawing attention to the precedents
for anti-viral vaccination in cancer provided by
control in this way of the naturally-occurring
herpesvirus-induced lymphomas of Marek's disease
in chickens, and sketching out how a vaccine
against EB virus might be developed. The EB virus-
determined membrane antigen (MA) was designated
as the appropriate immunogen since antibodies to it
were known to be virus neutralizing. Furthermore,
it was also pointed out that supplies of the cotton-
top tamarin should be secured since this Colombian
monkey was then about to be placed on the
endangered species list and was the susceptible
experimental animal of choice for biological experi-
ments with EB virus (Miller et al., 1977).
In the event a colony of the rare tamarins has
been set up and the dietary, management and
husbandry conditions for breeding have been
worked out (Kirkwood et al., 1983, 1985). The
nature of MA has been explored, and work in
several laboratories has demonstrated that it
consists of two, antigenically related, large glyco-
protein components with molecular weights of
340,000 and 270,000 daltons (MA gp340 and
gp270) (see Epstein, 1984 for review). In order to
purify MAgp340 efficiently a sensitive method was
needed to monitor production and a quantitative
radioimmunoassay was therefore developed. Using
this assay a molecular weight-based separation pro-
cedure was elaborated which included an important
new step for ensuring that the product was re-
natured and thus in an antigenic form (Morgan et
al., 1983). However, gp340 prepared in this way
had only a feeble capacity to induce neutralizing
antibodies when injected into animals and it was
therefore necessary to enhance its immunogenicity.
This was achieved by incorporating gp340 in
artificial liposomes, hollow fatty microspheres in
which the siting of the antigen resembles, at least to
some extent, the natural arrangement in cell
membranes.
Comparative studies of the immunogenicity of
various types of gp340 were undertaken. Full ex-
ploitation of these required a sensitive test for
specific antibodies and a rapid enzyme-linked im-
munosorbent assay (ELISA) was introduced
(Randle & Epstein, 1984). Following this a dose
and mode of administration of EB virus was
devised to ensure the induction of malignantVACCINATION TO PREVENT EB VIRUS CANCERS
lymphomas in 100% of unprotected tamarins
(Cleary et al., 1985) since only small numbers of
these animals were available for experiments.
Tamarins have now been immunized with purified
gp340 in liposomes and their serological responses
measured by ELISA and virus-neutralization tests.
In both pilot and confirmatory experiments animals
have been vaccinated with the prototype gp340 sub-
unit vaccine and have been shown to produce
powerful neutralizing antibodies. When these
animals were challenged with the 100% lympho-
magenic dose of EB virus they were protected
(Epstein et al., 1985).
It is of interest that when other tamarins were
immunized with gp340 prepared by a monoclonal
antibody immunoaffinity chromatography method
which does not bind all gp340 epitopes, good virus-
neutralizing antibodies were engendered but there
was no protection on challenge (Epstein et al.,
1986). Current investigations of the antibody
repertoires of animals immunized with gp340
prepared by the molecular weight-based method
compared to those immunized with material
purified using the monoclonal antibody are
beginning to shed light on the nature of the crucial
protecting epitopes.
Future strategies
In endemic areas of tropical Africa and New
Guinea BL is the most common cancer of children,
more frequent than all other children's tumours
added together (Burkitt, 1963), but in total this
tumour is not of very great significance and in
these endemic areas they have far more pressing
medical and public health problems. On the other
hand NPC is an important tumour in world cancer
terms. It is the most common cancer of men and
the second in importance for women in all popu-
lations of southern Chinese origin worldwide and
has a lesser, but nevertheless significantly raised,
incidence in certain other races of South East Asia
and in North and East Africa (Clifford 1970;
Shanmugaratnam, 1971). For this reason alone
there is a pressing need to develop something more
suitable for human use than the prototype sub-unit
vaccine which has proved successful in tamarins
(Epstein et al., 1985). The sequence of the viral
gene coding for MA has already been'determined
(Biggin, 1984) and consideration can be given to
the possibility of preparing synthetic gp340 peptides
since the sugar moiety of gp340 constitutes about
50% of the molecule and does not seem to be
essential for immunogenicity (Morgan et al., 1984).
The MA gene has also been cloned and there are
no insuperable difficulties to investigating its ex-
pression in bacterial, yeast, or mammalian cells.
Work in another direction has already succeeded in
incorporating the MA gene into the DNA of
vaccinia virus (Mackett & Arrand, 1985) to permit
direct expression during vaccination with that agent
and thus elicit EB virus-neutralizing antibodies.
When a vaccine against EB virus suitable for
testing in man becomes available how could trials
be undertaken? In the first instance, of course, a
very small number of informed volunteers would be
required to investigate the capacity of the vaccine
to induce protecting neutralizing antibodies. Once
this has been established and the safety of the
preparation assured, a double-blind trial could then
be undertaken. Groups of young adults can readily
be screened to detect those who have escaped
primary EB virus infection in childhood (University
Health Physicians and PHLS Laboratories, 1971)
and who are therefore at risk for delayed primary
infection which is accompanied by the clinical
manifestations of infectious mononucleosis (IM) in
50% of cases. This type of screening could be
applied to a group of new students entering a
University or College and could be followed by the
double-blind vaccine trial amongst those in the 'at
risk' category. The effectiveness of vaccination in
preventing infection and reducing the expected inci-
dence of IM would rapidly be evident. Thereafter
the effect of vaccination on infection and conse-
quential prevention of disease should be assessed in
a high incidence region for endemic BL. The
logistics of such a vaccine trial are no more
complicated than those which are curently being
overcome in the newly launched WHO thirty-year
prospective study of vaccination against hepatitis B
virus infection for the prevention of primary liver
cancer (International Agency for Research on
Cancer, 1985). In both cases it is necessary that
newborn or very young infants should receive the
vaccine to prevent primary infection which in
endemic areas, occurs in the very young. Since the
peak incidence of BL is at about the age of seven
(Burkitt, 1963), the influence of vaccination in an
endemic area would be apparent within a decade.
After this, the far more difficult problem will have
to be faced of vaccination to prevent NPC, a
disease of middle and later life (Clifford, 1970)
requiring the maintenance of immunity for a very
long time. Interest in intervention against EB virus
is particularly great in regions where undifferen-
tiated NPC is the leading cancer problem, and
because of this is seems likely that vaccination
programmes will be undertaken long before such
preliminaries as an IM study or a field trial against
BL have been completed.
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